Volume 95 Issue 20 | p. 19 | Concentrates
Issue Date: May 15, 2017

Pfizer gets Sangamo hemophilia treatment

Department: Business
Keywords: gene therapy, hemophilia, Pfizer

Pfizer has licensed Sangamo Therapeutics’ gene therapy programs for hemophilia A, including SB-525, which is expected to enter the clinic this quarter. Sangamo will get $70 million up front plus milestone payments of up to $300 million. Pfizer is already partnered with Spark Therapeutics on a gene therapy for hemophilia B. Last year Pfizer spent $150 million to acquire Bamboo Therapeutics and its gene therapy manufacturing facility.

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society